Table 1.

Treatment regimen

DayTreatment
−23Alemtuzumab test dose 3 mg IV*
−22Alemtuzumab 10 mg IV
−21Alemtuzumab 15 mg IV
−20Alemtuzumab 20 mg IV
−8Fludarabine 30 mg/m2 IV
−7Fludarabine 30 mg/m2 IV
−6Fludarabine 30 mg/m2 IV
−5Fludarabine 30 mg/m2 IV
−4Fludarabine 30 mg/m2 IV
−3Melphalan 140 mg/m2 IV; cyclosporine or tacrolimus dosed to maintain appropriate levels through day 100, and then tapered to day 180
−2Rest
−1Rest
0Bone marrow infusion
1Methotrexate 7.5 mg/m2 IV
3Methotrexate 7.5 mg/m2 IV
6Methotrexate 7.5 mg/m2 IV
7Methylprednisolone 1 mg/kg per day IV through day 28, and then taper granulocyte colony-stimulating factor 5 μg/kg body weight per day IV until absolute neutrophil count is ≥0.5 × 109/L for 3 consecutive days
  • * The test dose of alemtuzumab was administered 24 hours before the first dose, shown in this example on day −23.

  • Alemtuzumab treatment was required to be administered on 3 consecutive days but could begin on day −22, −21, or −20 and end on day −20, −19, or −18, respectively.